Curis Inc. ( (CRIS) ) has released its Q3 earnings. Here is a breakdown of the information Curis Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Curis Inc., a biotechnology firm, is advancing its clinical studies with a focus on emavusertib, a small molecule inhibitor targeting IRAK4 and FLT3, primarily in the treatment of various cancers. In its third-quarter 2025 report, Curis highlighted significant progress in its clinical trials, particularly in Primary CNS Lymphoma (PCNSL), Chronic Lymphocytic Leukemia (CLL), and Acute Myeloid Leukemia (AML). The company is preparing for several key presentations at upcoming medical conferences, showcasing promising data from these studies.
Curis reported a net loss of $7.7 million for the third quarter, an improvement from the $10.1 million loss in the same period last year. Revenues increased slightly to $3.2 million, driven by royalties from Genentech/Roche’s sales of Erivedge®. The company also managed to reduce its research and development expenses significantly, contributing to the improved financial performance.
The company is actively enrolling patients in its TakeAim Lymphoma study, aiming for accelerated approval filings in the US and EU. Additionally, Curis is initiating a Phase 2 study for CLL and is presenting initial data from its AML triplet study, which shows promising results in MRD conversion. These developments highlight Curis’s strategic focus on enhancing treatment outcomes in oncology.
Looking forward, Curis remains committed to advancing its clinical programs and expects further data releases in the coming months. The management is optimistic about the potential of emavusertib to transform treatment paradigms in oncology, although they acknowledge the need for additional funding to sustain operations beyond early 2026.